Karen A. Tourian, MD
- 7Articles
- 29.8KReads
- 2010–2015Active
- 15Collaborators
- 94Citations
About
Karen A. Tourian, MD, has published extensively on the treatment of major depressive disorder (MDD), focusing particularly on the efficacy, safety, and tolerability of desvenlafaxine. Her work includes randomized controlled trials and systematic reviews evaluating desvenlafaxine dosages and their impact on relapse prevention and weight changes in patients with MDD. Tourian's research, conducted between 2010 and 2015, contributes to understanding long-term management strategies for depression.
Publications
Efficacy of Desvenlafaxine 50 mg/d Versus Placebo in the Long-Term Treatment of Major Depressive Disorder: A Randomized, Double-Blind Trial
August 27, 2015
Efficacy, Safety, and Tolerability of Desvenlafaxine 50 mg/d for the Treatment of Major Depressive Disorder: A Systematic Review of Clinical Trials
June 24, 2010
Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.
